Stockscreener 앱 받기
24.12
2.42%
0.57
시간 외 거래:
24.13
0.010
+0.04%
전일 마감가:
$23.55
열려 있는:
$23.8
하루 거래량:
920.38K
Relative Volume:
0.79
시가총액:
$3.03B
수익:
$236.00M
순이익/손실:
$-369.00M
주가수익비율:
-7.5782
EPS:
-3.1828
순현금흐름:
$-489.00M
1주 성능:
+9.04%
1개월 성능:
+1.43%
6개월 성능:
+8.26%
1년 성능:
+177.24%
1일 변동 폭
$23.60
$24.75
1주일 범위
$21.98
$24.75
52주 변동 폭
$7.91
$28.72
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
24.12 | 3.04B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 개시 | H.C. Wainwright | Neutral |
| 2024-10-08 | 개시 | Wells Fargo | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-11-23 | 개시 | Evercore ISI | Outperform |
| 2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-09-27 | 개시 | Mizuho | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2018-10-09 | 개시 | Wedbush | Outperform |
| 2018-04-09 | 개시 | Citigroup | Buy |
| 2018-04-09 | 개시 | Goldman | Neutral |
| 2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Arcus Biosciences (RCUS) director receives 5,700 RSUs and 16,900 stock options - Stock Titan
Arcus Biosciences (RCUS) grants director RSUs and stock options - Stock Titan
Arcus Biosciences (RCUS) director receives RSU and stock option awards - Stock Titan
Arcus Biosciences counsel exercises 34,090 options | RCUS Insider Trading - Stock Titan
Director David L. Lacey receives RCUS stock awards at Arcus Biosciences (RCUS) - Stock Titan
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity - Stock Titan
Arcus Biosciences (RCUS) director Antoni Ribas receives RSU and option awards - Stock Titan
Arcus Biosciences (RCUS) director receives new RSU and stock option grants - Stock Titan
Arcus Biosciences (NYSE: RCUS) reports 2026 shareholder vote results - Stock Titan
Arcus Biosciences Jumps 6.9% Amid Sector-Wide Rally - AlphaStreet
Arcus Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
Arcus Biosciences Drops 7.0% After LifeSci Capital Initiates at Outperform - AlphaStreet
What Did Arcus Biosciences Highlight at the Goldman Sachs Healthcare Conference - Kavout
New hire at Arcus Biosciences gets stock options and RSUs - Stock Titan
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026Slideshow (NYSE:RCUS) 2026-06-09 - Seeking Alpha
Arcus Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Arcus, Bristol Myers team up to advance kidney cancer study - MSN
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $36.73, Implies 58% Upside - TradingView
LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46 - Moomoo
(RCUS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
A Look At Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness - Sahm
Is Arcus‑BMS Kidney Cancer Collaboration Altering The Investment Case For Arcus Biosciences (RCUS)? - Sahm
Arcus Biosciences (RCUS) Earnings Date and Reports 2026 - MarketBeat
Arcus Biosciences Jumps 5.7% Amid Sector-Wide Rally - AlphaStreet
RCUS Initiated Coverage by LifeSci Capital -- Rating Set to Outp - GuruFocus
Lifesci Capital Initiates Coverage on Arcus Biosciences (NYSE:RCUS) - MarketBeat
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study - Yahoo Finance
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating - Moomoo
With billions of dollars at stake, trio of Bay Area biotechs nail down deals - The Business Journals
BMY Collaborates with Arcus Biosciences on Clinical Trial for Ca - GuruFocus
Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment - marketscreener.com
Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial - marketscreener.com
New drug combo from Arcus and BMS targets advanced kidney cancer - Stock Titan
Arcus Biosciences Drops 6.0% Amid Sector-Wide Selling - AlphaStreet
Arcus Biosciences chief accounting officer sells $66,023 in stock By Investing.com - Investing.com South Africa
Arcus Biosciences chief accounting officer sells $66,023 in stock - Investing.com
Arcus Biosciences (RCUS) CAO 10b5-1 sale of 2,562 shares - Stock Titan
[144] Arcus Biosciences, Inc. SEC Filing - Stock Titan
Arcus Biosciences (RCUS) Surges 3.6%: Can the Breakout Hold Above Key Resistance?getLinesFromResByArray error: size == 0 - The League of Women Voters of Texas
Biotech Catalysts Put Three Small Caps On Watch - Kalkine Media
RCUS Stock Price, Quote & Chart | ARCUS BIOSCIENCES INC (NYSE:RCUS) - ChartMill
Arcus Biosciences joins Goldman Sachs chat, offers live webcast June 9 - Stock Titan
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Liquidity Mapping Around (RCUS) Price Events - Stock Traders Daily
Arcus halts Gilead-partnered late-stage trial for lung cancer drug - MSN
Arcus Biosciences (RCUS) Insider Trading Activity 2026 - MarketBeat
Truist Financial Initiates Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $35 - Moomoo
RCUS Assumes Buy by Truist Securities -- Price Target Raised to $35 - GuruFocus
Arcus Biosciences Coverage Assumed by Truist Securities at Buy - Moomoo
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):